Kornimate/medical-research-clean huggingface dataset:
chess-save score to stratify decompensation risk in compensated advanced chronic liver disease (chess2102)

Conditions: Compensated Advanced Chronic Liver Disease

Summary: compensated advanced chronic liver disease (cacld) was associated with a high rate of variceal bleeding, ascites, and hepatic encephalopathy due to portal hypertension. in these patients, esophagogastroduodenoscopy and hepatic venous pressure gradient were recommended methods to evaluate portal hypertension. however, non-invasive predictors of outcomes to stratify care remains needed. although the updated easl guideline has recommended that patients with liver stiffness \>20kpa or platelets \<150\*10\^9/l had the high risk of decompensation, the criteria remains to be validated. this international multicenter study aims to develop a novel chess-save score to further predict the risk of liver decompensation in cacld patients.

compensated advanced chronic liver disease (cacld) was associated with a high rate of variceal bleeding, ascites, and hepatic encephalopathy due to portal hypertension. in these patients, esophagogastroduodenoscopy and hepatic venous pressure gradient were recommended methods to evaluate portal hypertension. however, non-invasive predictors of outcomes to stratify care remains needed. although the updated easl guideline has recommended that patients with liver stiffness \>20kpa or platelets \<150\*10\^9/l had the high risk of decompensation, the criteria remains to be validated. this international multicenter study initialed and enrolled by chinese portal hypertension alliance (chess) aims to develop a novel chess-save score to further predict the risk of liver decompensation in cacld patients.

Eligibility criteria:
training and validation cohort inclusion criteria: * age more than 18 years; * fulfilled diagnosis of cacld based on radiological, histological features of liver cirrhosis exclusion criteria: * prior liver decompensation; * hepatocellular carcinoma; * prior liver transplantation; * portal vein thrombosis; * antiplatelet or anticoagulation; * without screening egd within six months of te; * incomplete follow-up data. hvpg cohort inclusion criteria: * age more than 18 years; * fulfilled diagnosis of cacld based on radiological, histological features of liver cirrhosis exclusion criteria: * prior liver decompensation; * hepatocellular carcinoma; * prior liver transplantation; * portal vein thrombosis; * antiplatelet or anticoagulation; * without screening egd within six months of te; * without hvpg measurement; * non-sinusoidal portal hypertension.

Keywords: liver stiffness platelets albumin varices compensated cirrhosis
study of addiction criteria in the elderly

Conditions: Depressive Disorder

Summary: patients over 65 years old who are exposed to alcohol or benzodiazepines will be recruited through the fragility assessment and addictions prevention day hospital, the addiction service and the geriatric post-emergency department. toulouse university hospital. the investigators will study descriptively the frequency of substance use disorder and the frequency of dsm-5 criteria associated with this diagnosis in a population of elderly subjects.

the hypothesis of this research is that some of the dsm-5 criteria for substance use disorder are more appropriate than others in people over 65 years of age. this study therefore aims to describe the frequency of the dsm-5 criteria for the substance use disorder in a population over 65 years of age and to link it secondarily to the severity of the addiction. the study is a descriptive study of a population of subjects over 65 years old. it aims to search for addiction criteria in this population by formulating the hypothesis of an addictive vulnerability relating to certain risk factors. to sensitize the detection of criteria, we chose among older subjects those who are most at risk because they are more exposed to the vulnerability factor relative to this population (physical disability, loss of autonomy, loneliness).

Eligibility criteria:
inclusion criteria: * to be over 65 * have given your non-oral opposition to participate in research * mini-mental state examination (mmse) greater than or equal to 24 * be part of one of the 3 inclusion services of the university hospital of toulouse * for 12 months, have daily consumption of benzodiazepine (at least once a day) and / or have excessive alcohol consumption as recommended by the american geriatric society (more than one unit of alcohol per day) ). exclusion criteria: * patient refusing to participate in the study * mmse less than 24 * acute decompensation of a psychiatric disorder * impossibility to understand or speak french * patient under the protection of justice

Keywords: geriatric addiction
respiratory variability and postoperative complications during thoracic lung resection.

Conditions: Lung Injury

Summary: postoperative respiratory complications (prc) represent a major public health issue. majority of prcs occur once the patient leaves the post-interventional monitoring room. identifying patients at risk for prc is therefore an important step for improving their post-operative care. in this context, any clinical marker making it possible to detect early alteration of the respiratory state in the postoperative phase deserves to be evaluated. this study is based on the hypothesis that measuring indices of respiratory variability which is synonymous with "good respiratory health" can be part of these markers. the measurement of respiratory variability will be done in patients with thoracic lung resection surgery before anesthetic induction and in the postoperative phase after extubation. it will be measured using a belt equipped with an external sensor allowing automatic and continuous analysis of thoracic movement by frequency analysis

postoperative respiratory complications (prc) represent a major public health issue. by prc, we mean acute respiratory distress, bronchospasm, pleural effusion, respiratory infection, atelectasis, aspiration pneumonia and pneumothorax. postoperative respiratory dysfunction reaches its peak in the 48 hours following surgery. majority of prcs therefore occur once the patient leaves the post-interventional monitoring room. identifying patients at risk for prc is an important step for improving their post-operative care. for this, there are predictive scores, notably the ariscat score, pre-operatively. however, there are few measurement methods to detect early alteration of the respiratory state in the postoperative phase. therefore, the physician in charge of the patient is alerted late if the patient deteriorates on the respiratory plan. in this context, any clinical marker making it possible to detect early alteration of the respiratory state in the postoperative phase deserves to be evaluated. therefore, this study is based on the hypothesis that measuring indices of respiratory variability can be part of these markers. consequently, this research which aims to describe these indices of respiratory variability is of major interest. respiratory variability is synonymous with "good respiratory health". by the opposite, the reduction of this same variability is pathological and indicates an increase in the level of load imposed on the respiratory system. the measurement of respiratory variability will be done in patients with thoracic lung resection surgery before anesthetic induction and in the postoperative phase after extubation. it will be measured using a belt equipped with an external sensor allowing automatic and continuous analysis of thoracic movement by frequency analysis

Eligibility criteria:
inclusion criteria: * patient, man or woman, who signed informed consent * patient older than 18 years old * patient admitted for planned thoracic resection surgery (lobectomy, bi-lobectomy, pneumonectomy) whatever the etiology is exclusion criteria: - none (medical aspects)
concordance of key actionable genomic alterations as assessed in tumor tissue and plasma in non small cell lung cancer

Conditions: Non Small Cell Lung Carcinoma

Summary: a study to determine the concordance of key actionable genomic alterations as assessed in tumor tissue and plasma from patients with non small cell lung carcinoma (nsclc)

this is a prospective clinical study to characterize the concordance of key clinically relevant genomic alterations in tumor tissue (biopsy/excision/cytology) and liquid biopsy (blood) using the genomic health lbmp in patients with stage iv non squamous nsclc, that are either newly diagnosed with metastatic disease or progressing on therapy (any line). tissue biopsy and blood collection (liquid biopsy) should be less than eight weeks apart and with no new systemic antitumoral treatment given in the interval between the tissue biopsy and blood collection. local assessment of tumor tissue samples will be performed at each participating institution as per their clinical standard of care practices and results from the local assessment of genomic alteration status will be used.

Eligibility criteria:
inclusion criteria: * subjects must be 18 years or older. * patients with stage iv non squamous nsclc who are either newly diagnosed or progressing on any treatment (progression defined as increasing tumor size or new metastatic lesions on clinical or imaging assessment). * patients with available tissue sample from a metastatic site or, if the patient presents with stage iv disease at diagnosis, from the primary tumor or a metastatic site. if a patient is progressing on egfr targeted therapy (erlotinib, gefitinib, afatinib), tumor tissue sample is required only if available. * no new systemic anti-tumor therapy administered in the interval between the tissue biopsy and collection of the blood sample. (interval not to exceed eight weeks). local radiation therapy is permitted. * able and willing to read, understand and sign an informed consent and health insurance portability and accountability act (hipaa) authorization, or equivalent privacy law, where this is applicable. exclusion criteria: * patients who are currently receiving therapy (targeted, immune- or chemotherapy) without sign of progression. * patients with squamous nsclc. * patients with more than 8 weeks between collection of tumor specimen and collection of blood sample for analysis. (not applicable for patients progressing on egfr targeted therapy with no biopsy at progression) * patients changing egfr therapy due to toxicity or preference without documented disease progression. * patients progressing on osimertinib treatment. * patients with brain metastases only. * inability to comply with study and/or follow-up procedures. * unable or unwilling to provide written informed consent.
zactima (an anti-egfr / anti-vegf agent) combined with docetaxel compared to docetaxel in non-small cell lung cancer

Conditions: Non-small Cell Lung Cancer; Lung Cancer

Summary: this large phase iii clinical study is studying the effect of vandetanib (zactima) in treating non-small cell lung cancer (nsclc). vandetanib is a new type of agent that targets the blood supply to a cancer tumour (through it's anti-vascular endothelial growth factor receptor (vegfr) properties) and the tumour cells themselves (through it's anti-endothelial growth factor receptor (egfr) actions). this study will look at the effects of vandetanib in lung cancer patients who have had their cancer re-appear after treatment with standard chemotherapy. this clinical study will test if the vandetanib anti-vegf and anti-egfr characteristics can deliver longer improved progression free survival and improved overall survival than docetaxel (taxotere) alone. all patients participating this clinical study will receive treatment with docetaxel, a commonly used treatment for recurrent non-small cell lung cancer. in addition, some patients will also receive vandetanib (zactima), an anti-egfr / anti-vegf agent. recent clinical research shows that vascular endothelial growth factor receptor (vegfr) inhibition, when used with standard chemotherapy, can lead to increased survival in advanced non-small cell lung cancer (nsclc) patients. other research shows that epidermal growth factor receptor (egfr) inhibitors, like erlotinib (tarceva) can also increase overall non-small cell lung cancer survival by killing tumour cells and stopping them from dividing.


Eligibility criteria:
inclusion criteria: lung cancer patients who answer true to the following statements are eligible to join this clinical study. * i have a confirmed diagnosis of locally advanced or metastatic non small cell lung cancer (stage iiib - iv) * i have had 1st line anti-cancer therapy. previous treatment with avastin (bevacizumab) in first line nsclc is allowed. exclusion criteria: lung cancer patients who answer true to the following are not eligible to join this clinical study. * i do not have non small cell lung cancer (nsclc) * i have received treatment with docetaxel (taxotere). prior treatment with paclitaxel is acceptable. * i have received 2nd line anti-cancer therapy (for example, patients with previous 2nd line non small cell lung cancer (nsclc) treatment with tarceva (erlotinib, osi-744), alimta (pemetrexed) are not eligible) * i have been treated with vegfr-tyrosine kinase inhibitors (tkis) (sunitinib, sorafenib, other vegf tkis). previous treatment with avastin (bevacizumab) in 1st line non small cell lung cancer is permitted. * i have a history of uncontrolled irregular heartbeat * i have a history of high blood pressure which has not been controlled with medication if you are unsure of the meaning of the inclusion and exclusion criteria above, please contact the call center number for help.

Keywords: non-small cell lung cancer nsclc
a pmcf investigation on exuding chronic wounds using exufiber® as primary dressing, and mepilex® border flex/comfort

Conditions: Wound Heal

Summary: the overall objective of this post market clinical follow-up (pmcf) investigation is to follow the progress of exuding chronic wounds to healing, or up to 12 weeks, whichever occurs first, consecutively using exufiber® as primary dressing, and mepilex® border flex (mepilex border comfort) as primary dressing.

this investigation is as a prospective, open, non-comparative, multi-centre investigation with the aim to follow exuding chronic wound progression. the investigation will include subjects from three populations suffering from exuding chronic wounds (venous leg ulcers, diabetic foot ulcers and pressure ulcers). the target wound for all subjects will initially be treated with exufiber® as primary dressing. as the wound progress and wound exudate production is reduced, the exufiber will be replaced by the mepilex border flex dressing. for ulcers located at sacrum or heel, the mepilex border heel or mepilex border sacrum will be used.

Eligibility criteria:
inclusion criteria: * provision of informed consent * both genders ≥18 years old. * exuding pressure ulcer, exuding diabetic foot ulcer or exuding venous leg ulcer (an exuding wound defined as one that requires highly absorbent dressing - as per clinical judgement) * chronic wound at least 4 weeks duration (chronic would be defined after 4 weeks). * abpi (within the last 3 months) ≥0.7 for both legs (if both present). if abpi \>1.4, then big toe pressure \>60mmhg is required or an alternative measurement verifying normal distal arterial flow. * at entry into the study, the ulcer or wound area should be 0.8 cm² - 70 cm². exclusion criteria: * known allergy/hypersensitivity to the dressing or its components. * subject included in other ongoing clinical investigation at present or during the past 30 days * pregnancy or lactation at time of study participation. * target wound dfu \<0.8 cm² , vlu \<3 cm² , pu \<1 cm² , post debridement (measured as greatest length x greatest width) * infected ulcer according to the judgment of the investigator defined as any wound condition requiring the prescription or continuation of systemic antibiotic therapy at recruitment. * other wounds within 3 cm from target wound * subject not suitable for the investigation according to the investigator's judgement.
study of imo-2055 in metastatic or locally recurrent clear cell renal carcinoma

Conditions: Renal Cell Carcinoma

Summary: * multi-center * randomized * open-label study of single agent imo-2055 * patients who have metastatic or locally recurrent clear cell renal carcinoma (rcc)

this is a study of 2 dose levels (0.16 or 0.64 mg/kg) of imo-2055 administered by weekly subcutaneous (sc) injections in two patient populations, treatment naïve or previously treated patients. each dose group (treatment naive or previously treated) will be randomized to receive one of the 2 doses being studied.

Eligibility criteria:
inclusion criteria: * histologically confirmed stage iv clear cell renal carcinoma with metastatic or locally recurrent disease that is not surgically resectable. * at least one measurable lesion * adequate organ function * any prior treatment of renal cell cancer was concluded at least 4 weeks prior. * if female and of childbearing potential, a negative serum pregnancy test performed and documented no more than 14 days before the first dose of study drug. exclusion criteria: * known untreated central nervous system (cns) metastasis * pre-existing autoimmune or antibody-mediated diseases * other significant medical disease.

Keywords: renal cell renal carcinoma metastatic recurrent treatment naive
the acute effect of propionate on energy homeostasis

Conditions: Obesity

Summary: the research project aims to examine the effect of a dietary supplement called propionate on how the human body in healthy adults aged (18- 65 years) responds to during fasting, exercise and following a liquid mixed meal test and how that would affect energy homeostasis and substrate oxidation.

dietary fibres have long been recognised for their important role in a healthy diet due to their negative association with, and even management of, chronic diseases such as obesity, diabetes, metabolic syndrome, cardiovascular disease and inflammatory-bowel disease among others.emerging evidence has suggested that these benefits could largely be attributed to short chain fatty acids (scfa) (acetate, propionate and butyrate), the main by-products of fibre fermentation in the gut. previous research has demonstrated that a long-term elevation in the scfa propionate significantly reduced body weight gain in overweight adults and reduced liver fat storage. the current project will examine potential mechanisms for the positive effect of propionate on energy homeostasis and metabolic profile.the effects of propionate on circulating glucose, insulin, gut hormones and lipid levels at rest, following moderate-intensity exercise and mixed meal tolerance test will be examined. to acutely increase propionate absorption from the gut the present project will use a simple nutritional supplement: sodium propionate in a hydroxypropylmethyl cellulose (hpmc) capsule. this capsule is coated with an enteric film which prevents gastric digestion until the capsule reaches the intestine. this nutritional supplement has been used in human volunteers in a previously approved ethics application (12/lo/1769: oral propionate and glucose homeostasis). a 5g acute dose of sodium propionate had previously been tested and reported no adverse effects . the mhra have confirmed that encapsulated sodium propionate is not classed as an investigative medicinal product.

Eligibility criteria:
inclusion criteria: * healthy volunteers (body mass index (bmi) of 18-35 kg/m2) * age between 18-65 years (inclusive) exclusion criteria: * weight change of ≥ 3kg in the preceding 2 months * current smokers * substance abuse * excess alcohol intake * pregnancy * diabetes * cardiovascular disease * cancer * gastrointestinal disease e.g. inflammatory bowel disease or irritable bowel syndrome * kidney disease * liver disease * pancreatitis * started new medication within the last 3 months likely to interfere with energy metabolism, appetite regulation and hormonal balance, including: anti-inflammatory drugs or steroids, antibiotics, androgens, phenytoin, erythromycin or thyroid hormones. * involved in current research or have recently been involved in any research prior to recruitment in the past 12 weeks.

Keywords: short chain fatty acids propionate energy expenditure lipid oxidation
a study for ctc expression and cfdna/rna assessment in metastatic breast cancer patients

Conditions: Metastatic Breast Cancer (MBC)

Summary: the purpose of this research is to learn if the cellsearch circulating tumor cells (ctc) test can help doctors in making decisions about treatment and monitoring of breast cancer. the test consists of diagnostic ctc counts (enumeration) and expression of biomarkers human epidermal growth factor receptor 2 (her2), estrogen receptor (er), and programmed death-ligand 1 (pd-l1) and cell free dna/rna (cfdna/rna) analysis.

a prospective, multicenter, observational study of cellsearch ctc enumeration, ctc her2, er, and pd-l1 expression, and msearch cfdna/rna results in subjects with histologically proven mbc. treatment for mbc will be chosen and performed by treating physicians/providers. eligible subjects will be enrolled after signing the icf. subjects will receive ctc enumeration, ctc her2, er, pd-l1 expression and, and msearch cfdna/rna assessments at baseline and first restaging as part of standard of care (soc). subjects will receive any additional cfdna/rna assessments as part of research collection. for all subjects 4 to 6 tubes will be collected at baseline and minimally before the first restaging visit. for any subsequent restaging visits a total of 3 to 4 tubes will be collected.

Eligibility criteria:
inclusion criteria: * invasive breast cancer with radiographic and/or clinical evidence of advanced metastatic or unresectable disease. * hr+/her2 negative or triple negative (tn) subjects prior to starting first line therapy or beyond in the metastatic setting. or her2+ subjects prior to starting second line therapy or beyond in the metastatic setting. * subject must have the ctc her2, er, pd-l1, and cfdna/rna tests ordered during routine patient care. * age \> 18 years. exclusion criteria: * participant is pregnant. * inability to provide blood samples based on the judgment of the treating physician.

Keywords: ctc cfdna cfrna